✦ LIBER ✦

52 THIRD LINE TREATMENT WITH A MODIFIED SCHEDULE OF VINORELBINE IN ADVANCED NSCLC PATIENTS WITH A POOR ECOG PERFORMANCE STATUS

✍ Scribed by E. Mazzoni; A. Nacci; P. Rizzo; L. Orlando; F. Sponziello; N. Calvani; P. Schiavone; M. D'Amico; A. Marino; P. Fedele; M.C. Chetri; M. Cinefra; S. Cinieri

Book ID: 117487952
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 46 KB
Volume: 36
Category: Article
ISSN: 0305-7372
DOI: 10.1016/s0305-7372(10)70078-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

O-52 ECOG 1599: Randomized phase II stud

O-52 ECOG 1599: Randomized phase II study of paclitaxel/carboplatin vs cisplatin/gemcitabine in performance status (PS) 2 patients with treatment-naive advanced NSCLC

✍ Langer, Corey J.; Stephenson, Patricia; Schiller, Joan; Tester, William J.; Rapo 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 184 KB

612 poster Treatment of squamous cell ca

612 poster Treatment of squamous cell carcinoma of the anus in poor performance status patients with a low dose chemoradiotherapy schedule

📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 236 KB

Paclitaxel Poliglumex/Carboplatin Is Sim

Paclitaxel Poliglumex/Carboplatin Is Similar to Paclitaxel/Carboplatin as First-Line Treatment in Elderly Patients with Advanced Non–Small-Cell Lung Cancer and a Poor Performance Status

✍ G. Kesava Reddy; Chandra P. Belani; Vinay K. Jain 📂 Article 📅 2005 🏛 CIG Media Group, LP. 🌐 English ⚖ 459 KB

O-53 A randomized phase II trial of gemc

O-53 A randomized phase II trial of gemcitabine, vinorelbine or docetaxel in the treatment of elderly and/or poor performance state patients with non-small cell lung cance (NSCLC)

✍ Leong, Swan Swan; Fool, Kian Fong; Tay, Miah Hiang; Toh, Chee Keong; Lim, Darren 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 359 KB

O-104 XYOTAXT™ vs. gemcitabine or vinore

O-104 XYOTAXT™ vs. gemcitabine or vinorelbine for the treatment of performance status (PS) 2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): The STELLAR 4 Phase III study

✍ O'Brien, M.; Sandler, A.; Popovich, A.; Ganchev, H.; Bogdanova, N.; Miziara, J. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 143 KB

78 FIRST-LINE MODIFIED SCHEDULE OF GEMCI

78 FIRST-LINE MODIFIED SCHEDULE OF GEMCITABINE INDUCES HIGH CLINICAL BENEFIT RATE WITHOUT SIGNIFICANT TOXICITY IN ELDERLY OR NOT ELDERLY ECOG PS 2 PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER

✍ A. Nacci; E. Mazzoni; P. Rizzo; L. Orlando; F. Sponziello; N. Calvani; P. Schiav 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 265 KB